Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 89661114 | 8966111 | 4 | F | 201207 | 20130322 | 20121217 | 20130331 | EXP | DE-AMGEN-DEUSP2012080147 | AMGEN | 77.00 | YR | M | Y | 87.00000 | KG | 20130331 | CN | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 89661114 | 8966111 | 1 | PS | Vectibix | 1 | INTRAVENOUS | 6 MG/KG, EVERY 14 DAYS | D | 125147 | 6 | MG/KG | UNKNOWN FORMULATION | |||||||
| 89661114 | 8966111 | 2 | C | METFORMIN | 1 | 850 MG, BID | D | 0 | 850 | MG | BID | ||||||||
| 89661114 | 8966111 | 3 | C | MAGNESIUM-DIASPORAL /00434501/ | 2 | UNK | D | 0 | |||||||||||
| 89661114 | 8966111 | 4 | C | DIASTABOL | 1 | 100 MG, UNK HALF TID | D | 0 | 100 | MG | TID | ||||||||
| 89661114 | 8966111 | 5 | C | XELODA | 1 | UNK | D | 0 | |||||||||||
| 89661114 | 8966111 | 6 | C | 5 FU | 1 | UNK | D | 0 | |||||||||||
| 89661114 | 8966111 | 7 | C | OXALIPLATIN | 1 | UNK | D | 0 | |||||||||||
| 89661114 | 8966111 | 8 | C | JALRA | 1 | 50 MG, QD | D | 0 | 50 | MG | QD | ||||||||
| 89661114 | 8966111 | 9 | C | ASS | 1 | 100 MG, QD | D | 0 | 100 | MG | QD | ||||||||
| 89661114 | 8966111 | 10 | C | OMEPRAZOLE | 1 | 20 MG, BID (EVERY EVENING) | D | 0 | 20 | MG | BID | ||||||||
| 89661114 | 8966111 | 11 | C | NORTRILEN | 1 | 25 MG, BID | D | 0 | 25 | MG | BID | ||||||||
| 89661114 | 8966111 | 12 | C | LEVOPAR | 1 | 125 MG, TID | D | 0 | 125 | MG | TID | ||||||||
| 89661114 | 8966111 | 13 | C | LAMOTRIGINE | 1 | 100 MG, QD | D | 0 | 100 | MG | QD | ||||||||
| 89661114 | 8966111 | 14 | C | SIMVASTATIN | 1 | 40 MG, UNK HALF QD | D | 0 | 40 | MG | QD | ||||||||
| 89661114 | 8966111 | 15 | C | BISOPROLOL | 1 | 2.5 MG, QD (HALF QD) | D | 0 | 2.5 | MG | QD | ||||||||
| 89661114 | 8966111 | 16 | C | ALLOPURINOL | 1 | 300 MG, UNK (HALF EVERY 2 DAY) | D | 0 | 300 | MG | QD | ||||||||
| 89661114 | 8966111 | 17 | C | TALCID | 2 | UNK (BEI BDARF -IF REQUIRED) | D | 0 | |||||||||||
| 89661114 | 8966111 | 18 | C | ZOPICLODURA | 1 | 7.5 MG, UNK (1/2 AS REQUIRED) | D | 0 | 7.5 | MG | |||||||||
| 89661114 | 8966111 | 19 | C | HALCION | 1 | 0.25 MG, UNK (1/2 AS REQUIRED) | D | 0 | .25 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 89661114 | 8966111 | 1 | Colon cancer |
| 89661114 | 8966111 | 5 | Colon cancer |
| 89661114 | 8966111 | 6 | Colon cancer |
| 89661114 | 8966111 | 7 | Colon cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 89661114 | 8966111 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 89661114 | 8966111 | Acne | |
| 89661114 | 8966111 | Arteriosclerosis | |
| 89661114 | 8966111 | Calcium deficiency | |
| 89661114 | 8966111 | Cardiac disorder | |
| 89661114 | 8966111 | Disability | |
| 89661114 | 8966111 | Diverticulitis | |
| 89661114 | 8966111 | Hepatic steatosis | |
| 89661114 | 8966111 | Hypoacusis | |
| 89661114 | 8966111 | Magnesium deficiency | |
| 89661114 | 8966111 | Metastases to liver | |
| 89661114 | 8966111 | Muscle spasms | |
| 89661114 | 8966111 | Osteoarthritis | |
| 89661114 | 8966111 | Rash pustular | |
| 89661114 | 8966111 | Skin exfoliation | |
| 89661114 | 8966111 | Skin fissures |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 89661114 | 8966111 | 1 | 20120614 | 20130217 | 0 |